Core Viewpoint - MicroPort NeuroTech (02172.HK) reported a revenue of RMB 382.9 million for the six months ending June 30, 2025, a decrease of 6.2% compared to RMB 408.2 million for the same period in 2024, primarily due to various factors affecting product sales and market dynamics [1] Revenue Breakdown - The revenue is mainly derived from hemorrhagic stroke products, carotid artery atherosclerosis products, and acute ischemic stroke products [1] - The overseas business continued to show strong growth, with revenue increasing approximately 67.4% year-on-year, and sales in the Asia-Pacific, North America, Latin America, and Europe, Middle East, and Africa regions all experienced varying degrees of rapid growth [1] - Revenue from hemorrhagic stroke products, including the spring coil series and the globally unique WILLIS intracranial covered stent, maintained rapid growth, while the market share of spring coils increased [1] - Revenue from carotid artery atherosclerosis products declined mainly due to the cessation of cooperation with original agents and the impact of centralized procurement in certain regions [1] Profitability Metrics - The company's gross profit margin was 73.4%, an increase of 1.1 percentage points from 72.3% in the same period last year, attributed to improved production efficiency [1] - The net profit recorded during the reporting period was approximately RMB 92.7 million [1] Dividend Announcement - The board of directors proposed an interim dividend of HKD 0.05 per ordinary share for the six months ending June 30, 2025 [1]
微创脑科学(02172.HK)中期收入3.83亿元 同比下降6.2%